Phase 1b Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Epithelial Ovarian Cancer

abstract
 

Highlights

• •Farletuzumab (FAR), a monoclonal antibody to folate receptor alpha, which is expressed in epithelial ovarian cancer (EOC).
• •FAR has shown activity against EOC in platinum-sensitive relapse when combined with carboplatin and a taxane.
• •Carboplatin in combination with pegylated liposomal doxorubicin (PLD) is a frequently used alterative regimen.
• •This safety study assessed the addition of FAR to carboplatin/PLD, with a view toward future larger studies.
• •This combination was generally well tolerated; adverse event profile was similar to that of carboplatin/PLD alone.